Letters from Drug Hunters #1 – Apr. 2022

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

To choose Molecules of the Month for June, our team reviewed hundreds of molecules from thousands of papers, press releases, conference presentations, and other sources. In this article, you'll find a curated selection of over 60 additional molecules from June that piqued our interest, along with highlights of some of our favorites and explanations of why they're worth keeping an eye on.

GSK and Roche strengthened their pipelines by forming groundbreaking collaborations that target neurodegenerative diseases and transcription factors, respectively. Meanwhile, Pep2Tango Therapeutics introduced a novel obesity treatment approach, and Amgen faced scrutiny over emerging data on its obesity drug candidate MariTide. This roundup covers the details behind these headlines.

In case you missed August’s business news, here’s a quick recap of five headlines, including an acquisition, three funding rounds, and a notable company closure.

To get you up to speed, here’s a recap of July’s molecules on the move, including potential upcoming approvals, key interim trial readouts, new IND submissions, and trial setbacks.